CN101553567A - 抑制或治疗与细胞内形成蛋白纤维状内含体或聚集体相关的疾病的方法 - Google Patents

抑制或治疗与细胞内形成蛋白纤维状内含体或聚集体相关的疾病的方法 Download PDF

Info

Publication number
CN101553567A
CN101553567A CNA2007800349538A CN200780034953A CN101553567A CN 101553567 A CN101553567 A CN 101553567A CN A2007800349538 A CNA2007800349538 A CN A2007800349538A CN 200780034953 A CN200780034953 A CN 200780034953A CN 101553567 A CN101553567 A CN 101553567A
Authority
CN
China
Prior art keywords
cell adhesion
sequence
phage
rgd
filamentous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800349538A
Other languages
English (en)
Chinese (zh)
Inventor
贝卡·所罗门
诺亚·沙仑
奥代德·格林斯泰因
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ramot at Tel Aviv University Ltd
Original Assignee
Ramot at Tel Aviv University Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ramot at Tel Aviv University Ltd filed Critical Ramot at Tel Aviv University Ltd
Publication of CN101553567A publication Critical patent/CN101553567A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/14011—Details ssDNA Bacteriophages
    • C12N2795/14111—Inoviridae
    • C12N2795/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/14011—Details ssDNA Bacteriophages
    • C12N2795/14111—Inoviridae
    • C12N2795/14161—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
    • C12N2810/405—Vectors comprising RGD peptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
CNA2007800349538A 2006-07-21 2007-07-19 抑制或治疗与细胞内形成蛋白纤维状内含体或聚集体相关的疾病的方法 Pending CN101553567A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83222906P 2006-07-21 2006-07-21
US60/832,229 2006-07-21

Publications (1)

Publication Number Publication Date
CN101553567A true CN101553567A (zh) 2009-10-07

Family

ID=38957610

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2007800349538A Pending CN101553567A (zh) 2006-07-21 2007-07-19 抑制或治疗与细胞内形成蛋白纤维状内含体或聚集体相关的疾病的方法

Country Status (8)

Country Link
US (1) US20090324554A1 (https=)
EP (1) EP2054515B1 (https=)
JP (1) JP2009544718A (https=)
CN (1) CN101553567A (https=)
AT (1) ATE541038T1 (https=)
AU (1) AU2007275258A1 (https=)
CA (1) CA2659032A1 (https=)
WO (1) WO2008011503A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104258372A (zh) * 2014-09-25 2015-01-07 中山大学 Rgd三肽在制备治疗阿尔茨海默症药物中的用途
CN106800590A (zh) * 2015-11-25 2017-06-06 中国科学院过程工程研究所 一种结合多种淀粉样蛋白单体和聚集体的多肽及其应用

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5214632B2 (ja) * 2007-12-04 2013-06-19 サッポロビール株式会社 骨吸収抑制剤
WO2009143470A1 (en) 2008-05-22 2009-11-26 Ramot At Tel Aviv University Ltd. Method for treating disease characterized by plaque
RU2011125971A (ru) * 2008-11-24 2012-12-27 Рамот Эт Тель-Авив Юниверсити Лтд. Способ лечения болезни паркинсона
BR112013023040A2 (pt) * 2011-03-11 2018-10-23 Univ Ramot bacteriófago filamentoso, composição farmacêutica, e, métodos para reduzir a formação de fibrilas de proteína tau ou para desagregar fibrilas pré-formadas de proteína tau em um paciente, e para tratar uma tauopatia degenerativa.
AU2012242455A1 (en) * 2011-04-15 2013-11-28 Molecular Transfer, Inc. Agents for improved delivery of nucleic acids to eukaryotic cells
WO2013016644A1 (en) 2011-07-27 2013-01-31 Neurophage Pharmaceuticals, Inc. Process for the production of filamentous bacteriophage
WO2013022717A1 (en) 2011-08-05 2013-02-14 Neurophage Pharmaceuticals, Inc. Pure filamentous bacteriophage and methods of producing same
CN114748605A (zh) 2011-11-29 2022-07-15 普罗克拉拉生物科学股份有限公司 噬菌体基因3蛋白组合物及作为淀粉样蛋白结合剂的用途
CN104870008B (zh) 2012-10-02 2019-10-01 普罗克拉拉生物科学股份有限公司 噬菌体的p3融合蛋白作为淀粉样蛋白结合剂的用途
KR20160010618A (ko) 2013-05-28 2016-01-27 뉴로페이지 파마슈티컬즈, 인크. 감소된 면역원성을 갖는 개질된 박테리오파아지 g3p 아미노산 서열을 포함하는 폴리펩티드
PL3227313T3 (pl) 2014-12-03 2022-05-09 Proclara Biosciences, Inc. Polipeptydy zawierające zmodyfikowaną sekwencję aminokwasową bakteriofaga g3p pozbawioną sygnału glikozylacji
WO2018215831A2 (en) * 2017-05-22 2018-11-29 National Hellenic Research Foundation Macrocyclic modulators of disease associated protein misfolding and aggregation
EP3684784B1 (en) * 2017-09-20 2024-03-27 Council of Scientific and Industrial Research Potent peptide inhibitors of protein aggregation
US20230372419A1 (en) * 2020-10-07 2023-11-23 Tatum Bioscience Inc. Live biotherapeutics secreting synthetic bacteriophages in the treatment of cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003509020A (ja) * 1999-09-03 2003-03-11 ラモット・ユニバーシティ・オーソリティ・フォー・アプライド・リサーチ・アンド・インダストリアル・ディベロップメント・リミテッド プラーク形成疾患の診断、治療、予防に有用な薬剤、組成物、その使用法
US20040013647A1 (en) * 1999-09-03 2004-01-22 Ramot At Tel-Aviv University Ltd. Methods and compositions for treating a plaque-forming disease
CA2477675C (en) * 2002-03-05 2013-05-21 Ramot At Tel-Aviv University Ltd. Immunizing composition and method for inducing an immune response against the .beta.-secretase cleavage site of amyloid precursor protein
WO2006050041A2 (en) * 2004-10-28 2006-05-11 Ramot At Tel Aviv University Ltd. Methods for reducing or inhibiting brain inflammation or for promoting neurogenesis
EP1853285B1 (en) * 2005-02-01 2011-03-16 Ramot at Tel-Aviv University Ltd. Method for treating inflammation associated with amyloid deposits and brain inflammation involving activated microglia
EP1863846B1 (en) * 2005-03-25 2009-07-22 Ramot at Tel-Aviv University Ltd. Human synthetic single-chain antibodies directed against the common epitope of mutant p53 and their uses

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104258372A (zh) * 2014-09-25 2015-01-07 中山大学 Rgd三肽在制备治疗阿尔茨海默症药物中的用途
CN106800590A (zh) * 2015-11-25 2017-06-06 中国科学院过程工程研究所 一种结合多种淀粉样蛋白单体和聚集体的多肽及其应用
CN106800590B (zh) * 2015-11-25 2021-04-09 杭州智鹤丹谷生物医药有限公司 一种结合多种淀粉样蛋白单体和聚集体的多肽及其应用

Also Published As

Publication number Publication date
WO2008011503A2 (en) 2008-01-24
US20090324554A1 (en) 2009-12-31
WO2008011503A3 (en) 2008-06-26
AU2007275258A1 (en) 2008-01-24
EP2054515B1 (en) 2012-01-11
EP2054515A2 (en) 2009-05-06
CA2659032A1 (en) 2008-01-24
ATE541038T1 (de) 2012-01-15
JP2009544718A (ja) 2009-12-17

Similar Documents

Publication Publication Date Title
EP2054515B1 (en) Use of a phage displaying a peptide from an adhesion protein for treating a disease associated with intracellular formation of protein fibrillar inclusions or aggregates
US8361458B2 (en) Method and filamentous phage for treating inflammation associated with amyloid deposits and brain inflammation involving activated microglia
Goyal et al. Rationally designed peptides and peptidomimetics as inhibitors of amyloid-β (Aβ) aggregation: Potential therapeutics of Alzheimer’s disease
US20040013647A1 (en) Methods and compositions for treating a plaque-forming disease
JP6440765B2 (ja) アミロイド結合剤としてのバクテリオファージのｐ３の使用
Ouberai et al. Synthesis and biological evaluation of clicked curcumin and clicked KLVFFA conjugates as inhibitors of β-amyloid fibril formation
US20110182948A1 (en) Method for treating disease characterized by plaque
JP2009529320A (ja) 脳への送達のための抗体および免疫複合体のバインダーとしてのプロテインａをディスプレイする繊維状バクテリオファージ
CN103476420A (zh) 用于治疗神经变性tau病的方法
AU766992B2 (en) Peptides containing N-substituted L-amino acids for preventing beta-strand association
EP1204679B1 (en) Peptides containing n-substituted d-amino acids for preventing beta-strand association
HK1110790B (en) Method for treating inflammation associated with amyloid deposits and brain inflammation involving activated microglia
Solomon Immunological concept in the treatment of Alzheimer's disease
HK1162964B (en) Method for treating parkinson' s disease using filamentous bacteriophage
HK1162964A1 (en) Method for treating parkinson' s disease using filamentous bacteriophage

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20091007